Finding a less invasive method of taking insulin seems to be all the rage these days. Although the once-hailed Exhubera fizzled away, researchers have not given up on the “holy grail” of oral insulin. Aside from Mannkind’s Afrezza, which is delayed and controversial, there’s another kind of oral insulin that might be making its mark in the diabetes marketplace… eventually.
Meet MonoSol Rx.
This New Jersey-based company has created PharmFilm, a thin, postage-sized film that…
Read more »
The world of type 2 diabetes drugs is wacky indeed. While Amylin’s long-acting version of Byetta — called Bydureon and predicted by many experts to become a blockbuster — is still held up at FDA, the agency approved a new oral drug earlier this month that is reportedly unremarkable except in the lawsuit it has spurred.
The drug is called linagliptin, brand name Tradjenta, a new oral DPP-4 inhibitor from Eli Lilly and Boehringer that…
Read more »
Society has many myths and misconceptions about people with diabetes. But even our own community can have some rather interesting “prejudices” about what diabetes is like for other people. After an article on a so-called “Civil War” between type 1 and type 2 diabetes appeared in the Chicago Tribune last fall, we at the ‘Mine decided to start sharing some personal stories of people living with type 2 diabetes, in order to better understand this…
Read more »
By
WilD on
March 19, 2011
You asked for it, you got it! OK, maybe it was mostly our idea… but we think you’re going to like it:
Say hello to our spicy new brand of diabetes advice column we’re calling Ask D’Mine. This series will be hosted by my good friend, veteran type 1, diabetes author and community educator Wil Dubois — with occasional input from Allison and myself.
“Need help navigating life with diabetes? Email us at AskDMine@diabetesmine.com“
This…
Read more »
Hearsay is that Al Mann, CEO of MannKind Corp., is one of those people who’s either brilliant, crazy, or a combination thereof. Probably the latter. And I guess you’d have to be to keep pushing ahead on developing a powdered inhalable insulin product in the wake of Pfizer’s colossal flop Exubera.
I interviewed Al Mann last November (when their product Afrezza was still spelled with an ‘s’). I thought his claims about this new mealtime…
Read more »
